AU2018265258B2 - Enveloped virus resistant to complement inactivation for the treatment of cancer - Google Patents

Enveloped virus resistant to complement inactivation for the treatment of cancer Download PDF

Info

Publication number
AU2018265258B2
AU2018265258B2 AU2018265258A AU2018265258A AU2018265258B2 AU 2018265258 B2 AU2018265258 B2 AU 2018265258B2 AU 2018265258 A AU2018265258 A AU 2018265258A AU 2018265258 A AU2018265258 A AU 2018265258A AU 2018265258 B2 AU2018265258 B2 AU 2018265258B2
Authority
AU
Australia
Prior art keywords
sequence
virus
protein
peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018265258A
Other languages
English (en)
Other versions
AU2018265258A1 (en
Inventor
Gabriel CASTILLE
Tianci Luo
Rene Molina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma Cinq LLC
Original Assignee
Pharma Cinq LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Cinq LLC filed Critical Pharma Cinq LLC
Publication of AU2018265258A1 publication Critical patent/AU2018265258A1/en
Application granted granted Critical
Publication of AU2018265258B2 publication Critical patent/AU2018265258B2/en
Assigned to PHARMA CINQ, LLC reassignment PHARMA CINQ, LLC Request for Assignment Assignors: WELLSTAT IMMUNOTHERAPEUTICS, LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018265258A 2017-05-10 2018-05-10 Enveloped virus resistant to complement inactivation for the treatment of cancer Active AU2018265258B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504120P 2017-05-10 2017-05-10
US62/504,120 2017-05-10
PCT/US2018/032018 WO2018209052A1 (en) 2017-05-10 2018-05-10 Enveloped virus resistant to complement inactivation for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2018265258A1 AU2018265258A1 (en) 2019-01-17
AU2018265258B2 true AU2018265258B2 (en) 2023-01-05

Family

ID=64105722

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018265258A Active AU2018265258B2 (en) 2017-05-10 2018-05-10 Enveloped virus resistant to complement inactivation for the treatment of cancer

Country Status (13)

Country Link
US (2) US11274141B2 (https=)
EP (1) EP3621635A4 (https=)
JP (1) JP7161940B2 (https=)
KR (3) KR20250118857A (https=)
CN (3) CN121343934A (https=)
AU (1) AU2018265258B2 (https=)
BR (1) BR112018075281A2 (https=)
CA (1) CA3026892A1 (https=)
IL (1) IL263979B2 (https=)
MX (1) MX2018015599A (https=)
NZ (1) NZ748798A (https=)
WO (1) WO2018209052A1 (https=)
ZA (1) ZA201808040B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN112759654A (zh) * 2019-11-06 2021-05-07 深圳普菲科生命科技有限公司 一种病毒囊膜蛋白装配系统及其方法和应用
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
US20240067936A1 (en) * 2021-02-26 2024-02-29 Sillajen, Inc. Oncolytic virus and uses thereof
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
KR20240003051A (ko) * 2022-06-29 2024-01-08 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
KR20240035360A (ko) * 2022-09-07 2024-03-15 신라젠(주) 항암 바이러스의 신규 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008061539A (ja) * 2006-09-05 2008-03-21 Osaka Univ ヒト補体制御因子発現遺伝子およびその利用
WO2016174407A1 (en) * 2015-04-27 2016-11-03 Ucl Business Plc Nucleic acid construct for expressing more than one chimeric antigen receptor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
JPH10313865A (ja) * 1997-05-15 1998-12-02 Deinabetsuku Kenkyusho:Kk ヒト補体制御因子が呈示されたベクター
US6475756B1 (en) * 1997-11-21 2002-11-05 Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) Development of viruses resistant to inactivation by the human complement system
JP4544497B2 (ja) 1997-12-22 2010-09-15 ユニバーシティ オブ テネシー リサーチ ファウンデーション 異種融合タンパク質を有する組変えラブドウイルス
NZ507063A (en) * 1998-04-02 2003-11-28 Rigel Pharmaceuticals Inc Self-dimerising peptides causing the formation of compact structures
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
CA2574282A1 (en) 2004-07-21 2006-03-02 Dana-Farber Cancer Institute, Inc. Lentiviral vectors and uses thereof
WO2008118258A2 (en) * 2007-02-06 2008-10-02 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
JP5332064B2 (ja) * 2007-03-01 2013-11-06 ウェルスタット イムノセラピューティクス， エルエルシー 炎症により特徴付けられる疾患の治療
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
US20140206850A1 (en) 2011-04-29 2014-07-24 Keygene N.V. Glyphosate resistance enhancement
EP2704744B1 (en) 2011-05-05 2019-04-24 Wellstat ImmunoTherapeutics, LLC Complement factor b analogs and their uses
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
AU2015244039B2 (en) * 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
DK3143134T3 (da) * 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
WO2017197525A1 (en) 2016-05-19 2017-11-23 Evgin Laura Pseudotyped oncolytic rhabdoviruses and their use in combination therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008061539A (ja) * 2006-09-05 2008-03-21 Osaka Univ ヒト補体制御因子発現遺伝子およびその利用
WO2016174407A1 (en) * 2015-04-27 2016-11-03 Ucl Business Plc Nucleic acid construct for expressing more than one chimeric antigen receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SPITZER D ET AL, "Complement-protected amphotropic retroviruses from murine packaging cells", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, (1999-07-20), vol. 10, no. 11, pages 1893 - 1902. *

Also Published As

Publication number Publication date
IL263979A (en) 2019-02-28
EP3621635A4 (en) 2021-02-24
CA3026892A1 (en) 2018-11-15
JP7161940B2 (ja) 2022-10-27
CN121343935A (zh) 2026-01-16
IL263979B2 (en) 2023-09-01
JP2020519230A (ja) 2020-07-02
EP3621635A1 (en) 2020-03-18
KR20250118857A (ko) 2025-08-06
CN121343934A (zh) 2026-01-16
RU2018146446A3 (https=) 2021-09-10
NZ748798A (en) 2026-03-27
ZA201808040B (en) 2019-09-25
KR20240073085A (ko) 2024-05-24
CN109414483B (zh) 2025-10-24
US20190194292A1 (en) 2019-06-27
MX2018015599A (es) 2019-05-16
IL263979B1 (en) 2023-05-01
CN109414483A (zh) 2019-03-01
US11274141B2 (en) 2022-03-15
KR102839445B1 (ko) 2025-07-28
BR112018075281A2 (pt) 2020-02-11
WO2018209052A1 (en) 2018-11-15
KR20200005721A (ko) 2020-01-16
RU2018146446A (ru) 2021-06-10
KR102662049B1 (ko) 2024-05-23
AU2018265258A1 (en) 2019-01-17
US20220169701A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
AU2018265258B2 (en) Enveloped virus resistant to complement inactivation for the treatment of cancer
AU2020201190B2 (en) Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
CN112522271B (zh) 一种sgRNA及其应用
KR20220066914A (ko) 부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료
CN112680466B (zh) 一种表达人源ace2的动物模型及其用途
KR102673828B1 (ko) off-the-shelf 줄기세포 및 면역세포, 이를 포함하는 약학적 조성물
KR101258949B1 (ko) 활성형 재조합 혈액응고 9인자의 대량생산 방법
CN117715660A (zh) 右心室致心律失常性心肌病的基因治疗组合物和治疗
CN109055428A (zh) 一种重组腺相关病毒载体及其制备方法与应用
TW202233829A (zh) 嵌合抗原受體(car) nk細胞及其用途
CN108379597B (zh) 一种基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
KR101885438B1 (ko) 유전자치료 벡터시스템 및 전구약물 유전자
CN112342228B (zh) 表达抗vegf融合蛋白的aav病毒载体及其应用
CN114107390B (zh) 一种用于表达抗体IgG1的rAAV载体及其应用
CN112877351A (zh) 一种用于防治新冠病毒感染的重组质粒、重组乳酸杆菌表达系统及其应用
CN111793632A (zh) 变异的Gsdmd-C核酸片段，包含所述核酸片段的载体及应用
CN112301058B (zh) 一种重组腺相关病毒载体及其制备方法与应用
TWI902721B (zh) 前庭支持細胞啟動子及其用途
RU2791051C2 (ru) Оболочечный вирус, резистентный к инактивации комплементом, для лечения злокачественных новообразований
CN110225977B (zh) 基因治疗载体系统和药物前体基因
CN109735558B (zh) 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
CN112301057B (zh) 一种重组腺相关病毒载体及其制备方法与应用
US20020103144A1 (en) Retroviral gene transfer vectors
CN114686521A (zh) 一种重组腺相关病毒载体及其制备方法与应用
CN111088204A (zh) 表达Caspase-3重组scFv78的重组大肠杆菌及其功能验证方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PHARMA CINQ, LLC

Free format text: FORMER OWNER(S): WELLSTAT IMMUNOTHERAPEUTICS, LLC